ICPT Intercept Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ICPT

Price (delayed)

$11.12

Market cap

$463.56M

P/E Ratio

1.99

Dividend/share

N/A

EPS

$5.58

Enterprise value

$733.58M

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded ...

Highlights
ICPT's debt has dropped by 54% year-on-year
ICPT's revenue is up by 12% year-on-year and by 3.1% since the previous quarter
The equity has soared by 118% YoY but it has contracted by 28% from the previous quarter
The quick ratio has declined by 25% year-on-year
The EPS has declined by 15% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.interceptpharma.com
Peers: BMY LLY ENZN GILD

Key stats

What are the main financial stats of ICPT
Market
Shares outstanding
41.69M
Market cap
$463.56M
Enterprise value
$733.58M
Valuations
Price to earnings (P/E)
1.99
Price to book (P/B)
6.9
Price to sales (P/S)
1.57
EV/EBIT
3.27
EV/EBITDA
3.25
EV/Sales
2.49
Earnings
Revenue
$294.52M
EBIT
$224.49M
EBITDA
$225.41M
Free cash flow
-$58.81M
Per share
EPS
$5.58
Free cash flow per share
-$1.41
Book value per share
$1.61
Revenue per share
$7.07
TBVPS
$12.1
Balance sheet
Total assets
$504.09M
Total liabilities
$436.9M
Debt
$333.04M
Equity
$67.19M
Working capital
$283.34M
Liquidity
Debt to equity
4.96
Current ratio
2.37
Quick ratio
2.24
Net debt/EBITDA
1.2
Margins
EBITDA margin
76.5%
Gross margin
99.7%
Net margin
70.3%
Operating margin
-24.8%
Efficiency
Return on assets
39.1%
Return on equity
N/A
Return on invested capital
33.1%
Return on capital employed
75.6%
Return on sales
76.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ICPT stock price

How has the Intercept Pharmaceuticals stock price performed over time
Intraday
3.63%
1 week
8.38%
1 month
-28.95%
1 year
-37%
YTD
-10.11%
QTD
-17.2%

Financial performance

How have Intercept Pharmaceuticals's revenue and profit performed over time
Revenue
$294.52M
Gross profit
$293.54M
Operating income
-$73.12M
Net income
$206.97M
Gross margin
99.7%
Net margin
70.3%
Intercept Pharmaceuticals's operating margin has increased by 26% YoY but it has decreased by 3.8% QoQ
Intercept Pharmaceuticals's operating income has increased by 17% YoY but it has decreased by 7% QoQ
ICPT's revenue is up by 12% year-on-year and by 3.1% since the previous quarter
Intercept Pharmaceuticals's gross profit has increased by 12% YoY and by 3.1% QoQ

Growth

What is Intercept Pharmaceuticals's growth rate over time

Valuation

What is Intercept Pharmaceuticals stock price valuation
P/E
1.99
P/B
6.9
P/S
1.57
EV/EBIT
3.27
EV/EBITDA
3.25
EV/Sales
2.49
The EPS has declined by 15% since the previous quarter
The equity has soared by 118% YoY but it has contracted by 28% from the previous quarter
ICPT's price to sales (P/S) is 79% lower than its 5-year quarterly average of 7.4 and 8% lower than its last 4 quarters average of 1.7
ICPT's revenue is up by 12% year-on-year and by 3.1% since the previous quarter

Efficiency

How efficient is Intercept Pharmaceuticals business performance
The ROS has declined by 10% since the previous quarter
Intercept Pharmaceuticals's return on assets has decreased by 7% QoQ
Intercept Pharmaceuticals's return on invested capital has increased by 7% QoQ

Dividends

What is ICPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ICPT.

Financial health

How did Intercept Pharmaceuticals financials performed over time
The total assets is 15% greater than the total liabilities
Intercept Pharmaceuticals's total liabilities has shrunk by 50% YoY and by 5% QoQ
The quick ratio has declined by 25% year-on-year
The equity has soared by 118% YoY but it has contracted by 28% from the previous quarter
ICPT's debt has dropped by 54% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.